Precision Medicine in Oncology®

As the treatment paradigm in urothelial cancer expands to include agents directed at various targets, NECTIN-4 has emerged as a promising treatment target.

Jason Porter, MD, discusses the progress in the development of treatment options for patients with KRAS G12C-mutated non–small cell lung cancer.

The FDA has approved erdafitinib (Balversa) for select adult patients with locally advanced or metastatic urothelial carcinoma harboring FGFR3 alterations.

Genetic screening and testing have only recently become an integral part of cancer care.

As novel drugs targeting the AURKA pathway continue to advance through the development pipeline, alisertib has emerged as an agent of particular note.

Investigators hope that first-in-class agents will combat dysfunction of the Hippo pathway by inhibiting the transcription function of TEAD-YAP.function of TEAD-YAP.

The European Commission has granted conditional marketing authorization to adagrasib for patients with KRAS G12C+ advanced non–small cell lung cancer.

Vivek Subbiah, MD, emphasizes the need for improved guidance on practical toxicity management for various FGFR-altered malignancies, highlights best practices for monitoring and managing the most common on-target toxicities associated with FGFR inhibitors, and discusses the key implications of this review for those utilizing FGFR inhibitors.

Pooja Advani, MBBS, MD, details the encouraging activity of antibody-drug conjugates in triple-negative breast cancer, the importance of utilizing next-generation sequencing to inform treatment selection after progression on CDK4/6 inhibitors in this disease setting, and more.

Andrew Ip, MD, discusses findings from a study on the use of next-generation sequencing of flow cytometry CD markers and machine learning as a replacement to flow cytometry analysis for the diagnosis of hematologic neoplasms.

In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.

In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.

Alexander Drilon, MD, highlights how the approval of repotrectinib addresses the need for improved therapies for patients who have progressed on a previous TKI and delves into notable neurologic toxicities seen with the agent.

Revumenib demonstrated clinically meaningful activity, including high response and minimal residual disease negativity rates, in heavily pretreated patients with KMT2A-rearranged acute leukemia.

In this seventh episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss how artificial intelligence tools may be utilized to improve wait time for treatment, to provide more time for provider-patient interactions, and more.

The addition of inavolisib to palbociclib and fulvestrant improved progression-free survival vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer.

In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.

In this sixth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss potential opportunities to leverage artificial intelligence tools in cancer screening, diagnosis, staging, and prognosis.

Christopher M. Gallagher, MD, discusses unmet needs surrounding the use of antibody-drug conjugates, as well as questions remaining with other approved agents in breast cancer.

Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.

In this fifth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss the need for evidence to support the utilization of different artificial intelligence tools in healthcare.

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of the next-generation ROS1 TKI taletrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer with prior exposure to a ROS1 TKI.

Bayer has voluntarily recalled 1 lot of the larotrectinib 20 mg/mL oral solution that is packaged in 100-mL glass bottles because of the presence of Penicillium brevicompactum contamination that was observed during ongoing, routine stability testing.

Alan Tan, MD, discusses the ongoing potential utility of circulating tumor DNA in patients with renal cell carcinoma and highlights how this approach is being used in his own practice.

The FDA has approved the FoundationOne® CDx for use as a companion diagnostic to identify patients with advanced hormone receptor–positive, HER2-negative advanced breast cancer who may be eligible for treatment with the combination of capivasertib and fulvestrant.

MRT-2359 had acceptable tolerability with a favorable pharmacokinetic and pharmacodynamic profile in heavily pretreated patients with MYC-driven solid tumors, including lung cancer and high-grade neuroendocrine cancer.

A supplemental biologics license application seeking the approval of amivantamab in combination with platinum-based chemotherapy for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 19 deletions has been submitted to the FDA.

In this fourth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain the importance of having a diverse editorial board behind a new journal on artificial intelligence in precision oncology.

The HER2-directed CAR-macrophage therapy CT-0508 displayed a tolerable safety profile and signs of antitumor activity in patients with a variety of solid tumors.

Christopher M. Gallagher, MD, discusses treatment sequencing considerations with antibody-drug conjugates in patients with HER2-low metastatic breast cancer.